Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Slides:

Advertisements

Similar presentations

Review of a patient with confirmed pulmonary veno-occlusive disease and nonmatched perfusion defects. a) Ventilation/perfusion lung scan with multiple.

Advertisements

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

A) Pulmonary veno-occlusive disease (PVOD) with partial thrombotic occlusion of the lumen of a medium-sized vein (haematoxylin and eosin stain, 200× original.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Selection of patients: 248 consecutive patients with newly diagnosed pre-capillary pulmonary hypertension were included in the study. Selection of patients:

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.

Kaplan–Meier survival curves for outcomes among chronic obstructive pulmonary disease (COPD) patients without obstructive sleep apnoea (OSA) (COPD group),

Elastic staining of paraffin-embedded lung tissue.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Significance of the principal genetic variants associated with familial pulmonary fibrosis by their strength and frequency. Significance of the principal.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in a patient with pulmonary arterial hypertension and preserved physiological.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Patient with inoperable chronic thromboembolic pulmonary hypertension showing a typical aspect of subpleural hypoperfusion at the capillary phase of pulmonary.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

Relationship between pulmonary vascular obstruction (PVO) and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension (CTEPH) and.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

A) Chest radiograph of a 37-year-old male mountaineer with high-altitude pulmonary oedema (HAPE) showing a patchy to confluent distribution of oedema,

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH) patients and asymptomatic relatives in the French PAH network (adult cohort). Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH) patients and asymptomatic relatives in the French PAH network (adult cohort). Reproduced and modified from [49] with permission. Barbara Girerd et al. Eur Respir Rev 2017;26:170037 ©2017 by European Respiratory Society